Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab + Tuvonralimab + SOX after heterogeneous radiotherapy in HER2-negative advanced gastric/GEJ adenocarcinoma
ChiCTR2600129264Phase 4Not yet recruiting
- Sponsor
- Tongji Hospital
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of iparomlimab and tuvonralimab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Tongji Hospital. Primary endpoint: Progression-Free Survival. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
iparomlimabtuvonralimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2600129264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600129264.